Clinical Trial Update: Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps

View source ↗

Summary

This document reports the completed regulatory post-marketing surveillance study of Xolair (omalizumab) for chronic rhinosinusitis with nasal polyps. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Rhinosinusitis With Nasal Polyps | Status: COMPLETED